FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> pandemic | Vaccine | GlaxoSmithKline

GSK's secret vaccine adjuvant draws attention

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

GlaxoSmithKline's success advancing two pandemic vaccines--Prepandrix and Pandemrix--relies on a secret formula that drives efficacy of a low antigen dose in these adjuvated products. According to In Vivo, Glaxo has been careful to keep the proprietary adjuvant secret throughout the approval process. As Glaxo has noted, a pandemic would require massive quantities of vaccine for any effective campaign to protect populations--and adjuvants are considered a key to making sure that vaccine stocks can be spread far and wide enough to prevent an outbreak. At some point, In Vivo notes, Glaxo will have to either unveil the adjuvant to European or U.S. regulatory officials.

- read the feature in In Vivo

Related Articles:
GSK pre-pandemic vaccine shows promise. Report
GSK wins EMEA approval for pandemic vaccine. Report
HHS awards H5N1 contracts. Report

More stories about pandemic   Vaccine   GlaxoSmithKline  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.